Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LiRA2: Liraglutide in Prediabetic ESRD
NCT02284230Phase 2Withdrawn
- Start
- Dec 2014
- Primary completion
- Aug 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prediabetes comparing Liraglutide with Placebo (2 arms). Primary endpoint: Plasma glucose during oral glucose tolerance test at 26 weeks. Planned start Dec 2014; status: withdrawn.
02
Drugs
03
Conditions
prediabetes
Beyond the preview
Go deeper on NCT02284230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02284230.